Hikma Pharmaceuticals PLC Stock Value
Hikma Pharmaceuticals PLC Company Info
EPS Growth 5Y
3,37%
Market Cap
£2,84 B
Long-Term Debt
£1,07 B
Annual earnings
N/A
Dividend
£0,63
Dividend Yield
4,76%
Founded
1978
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
£18,60
40.17%
Last Update: 04/09/2026
Analysts: 11
Highest Price Target £26,40
Average Price Target £18,60
Lowest Price Target £13,52
In the last five quarters, Hikma Pharmaceuticals PLC’s Price Target has fallen from £29,09 to £24,26 - a -16,60% decrease. Nine analysts predict that Hikma Pharmaceuticals PLC’s share price will increase in the coming year, reaching £18,60. This would represent an increase of 40,17%.
Top growth stocks in the health care sector (5Y.)
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC engages in the development, manufacture, and marketing of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates primarily in the United States, Europe, the Middle East, and North Africa.
Segments
The company operates in three segments: Branded Pharmaceuticals, Generic Pharmaceuticals, and Injectable Pharmaceuticals.
Branded
The Branded Pharmaceuticals segment develops, manufactures, and...
Hikma Pharmaceuticals PLC Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Revenue distribution by sectors:**
- Generics: 50%
- Specialty Pharmaceuticals: 30%
- Branded Products: 20%
**TOP 3 markets and their percentage shares:**
- USA: 45%
- Middle East and North Africa (MENA): 35%
- Europe: 15%
Hikma Pharmaceuticals PLC generates the majority of its revenue from the...
At which locations are the company’s products manufactured?
**Production sites of Hikma Pharmaceuticals:**
Hikma Pharmaceuticals PLC operates production facilities in several countries, including:
- **Jordan:** The company's headquarters and several production plants are located here.
- **USA:** Hikma has significant production capacity in the United...
What strategy does Hikma Pharmaceuticals PLC pursue for future growth?
**Revenue Growth:** Estimated 8-10% annually (2025 forecast)
**Focus Areas:** Generics, Specialty Pharmaceuticals, Market Diversification
Hikma Pharmaceuticals PLC pursues a growth strategy based on expanding its generics portfolio and strengthening its position in the specialty pharmaceuticals se...
Which raw materials are imported and from which countries?
**Important raw materials:** Active ingredients (API), excipients, packaging materials
**Main supplying countries:** India, China, Germany, USA
Hikma Pharmaceuticals PLC sources a variety of raw materials that are essential for the production of their pharmaceutical products. The most important m...
How strong is the company’s competitive advantage?
**Market share in the generic sector:** Approximately 5% (2024, estimate)
**EBITDA margin:** 22% (2024)
**R&D expenses:** 7% of revenue (2024)
Hikma Pharmaceuticals PLC has a significant competitive advantage in the generic sector, especially due to its strong presence in the USA and the Middle...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** approx. 70% (estimated for 2025 based on historical data)
**Insider Buys/Sells:** No significant transactions in the last year (estimated for 2025)
Hikma Pharmaceuticals PLC has traditionally had a high proportion of institutional investors, indicating the trust o...
What percentage market share does Hikma Pharmaceuticals PLC have?
**Market share of Hikma Pharmaceuticals:** Estimated around 3-4% (2025)
**Top competitors and their market shares:**
1. **Pfizer Inc.:** around 10-12%
2. **Novartis AG:** around 9-11%
3. **Roche Holding AG:** around 8-10%
4. **Sanofi:** around 7-9%
5. **Merck & Co., Inc.:** around 6-8%
6. **Gla...
Is Hikma Pharmaceuticals PLC stock currently a good investment?
**Revenue Growth:** 8.5% (2024)
**Profit Growth:** 10.2% (2024)
**R&D Expenses:** 6.3% of revenue (2024)
Hikma Pharmaceuticals PLC recorded solid revenue growth of 8.5% in 2024, driven by strong demand for generic drugs and successful expansion into new markets. The 10.2% profit growth indicate...
Does Hikma Pharmaceuticals PLC pay a dividend – and how reliable is the payout?
**Dividend yield:** 2.5% (2024)
**Dividend history:** Continuous payout for over 10 years
Hikma Pharmaceuticals PLC has been paying dividends in recent years, indicating a stable dividend policy. The dividend yield was around 2.5% in 2024, which can be considered moderate compared to other comp...
